Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Peking University Third Hospital currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, though they are concentrated within 1 distinct art unit. This concentration suggests a narrow technical focus for the portfolio's current prosecution activity, as the matters are being evaluated within the same departmental framework.
The busiest examiner for this portfolio is HAGHIGHATIAN, MINA, who is responsible for 1 pending office action. Since this represents a portion of the pending office actions, the hospital's prosecution strategy relies on navigating a small group of examiners. The art unit provides a stable regulatory environment for the current filings. The presence of the distinct examiners ensures that while the technical field is narrow, the hospital must still address the individual perspectives of different reviewers. This approach requires careful coordination to ensure consistent outcomes across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | — |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | — |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18932725 | TISSUE-DERIVED IMPLANT USEFUL FOR CARTILAGE REGENERATION | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18701160 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | KWON, YONG SOK | — | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial